Idaho Falls, ID – October 22th, 2025 – International Isotopes Inc. (OTCQB: INIS) (“INIS” or the “Company”), a leading provider of radiopharmaceuticals, radioisotope products, and nuclear medicine solutions, has appointment of Dr. Duke W. Fu to its Board of Directors, effective October 10th, 2025. Dr. Fu, a Board Certified Nuclear Pharmacist with over 20 years of leadership in radiopharmaceutical operations and regulated industries, will also serve on the Company’s Audit Committee.
Dr. Fu holds a Doctor of Pharmacy and a Master of Business Administration from The University of New Mexico and has a Post Doctorate Specialization as a Board-Certified Nuclear Pharmacist from Purdue University. His career spans CEO and other leadership roles in healthcare distribution, nuclear pharmacy management, and innovative startup scaling, with a proven track record of driving operational excellence, regulatory compliance, and market expansion. Dr. Fu brings deep expertise in cGMP production, and public board directorship. Since 2015, Dr. Fu has served as the chief executive officer of Green Therapeutics and held the positions of interim chief executive officer and chief operating officer of Australis Capital from 2020 to 2022. Previously, Dr. Fu was a managing partner at Biotech Pharmacy, which was acquired by Cardinal Health in 2009. Dr. Fu subsequently continued as a manager at Cardinal Health. In both roles, Dr. Fu oversaw nuclear pharmaceutical manufacturing and the commercial development of novel nuclear imaging and therapeutic agents.
“Dr. Fu’s deep knowledge of nuclear medicine and regulatory frameworks makes him an invaluable addition to our Board,” said Christopher Grosso, Chairman of INIS. “His insights will strengthen our governance and drive our strategic objectives forward.”
“It is a privilege to join the Board of Directors of International Isotopes Inc. I have long admired the company’s leadership in advancing innovative isotope technologies and its commitment to excellence, safety, and sustainability. I look forward to working with my fellow board members and the executive team to support the company’s continued growth and strategic vision in the years ahead.”
****
About International Isotopes Inc.
International Isotopes Inc. (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. INIS manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. INIS provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients INIS manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. The Company also manufactures Cobalt-60 sealed source products. For more information, visit intisoid.com.
Safe Harbor Statements
Certain statements in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company’s future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of International Isotopes Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company’s filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2024. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward- looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
International Isotopes Contact:
IR@intisoid.com
intisoid.com
208.524.5300